Simulating the Impact of a Molecular 'Decision-Process' on Cellular
  Phenotype and Multicellular Patterns in Brain Tumors by Athale, Chaitanya et al.
C. Athale et al.: Molecular Decision Process in Tumors 
   
 1
Simulating the Impact of a Molecular ‘Decision-Process’ on  
Cellular Phenotype and Multicellular Patterns in Brain Tumors 
 
 
Chaitanya Athale 1, Yuri Mansury 1 and Thomas S. Deisboeck 1,* 
 
 
1 Complex Biosystems Modeling Laboratory, Harvard-MIT (HST) Athinoula A. Martinos 
Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA 02129.  
 
 
 
Running Title:  Molecular Decision Process in Tumors 
Keywords:  Glioma, epidermal growth factor receptor, gene-protein network, agent-
based model, migration, proliferation. 
 
 
 
 
*Corresponding Author:  
 
Thomas S. Deisboeck, M.D.  
Complex Biosystems Modeling Laboratory  
Harvard-MIT (HST) Athinoula A. Martinos Center for Biomedical Imaging  
Massachusetts General Hospital-East, 2301  
Bldg. 149, 13th Street  
Charlestown, MA 02129 
Tel: 617-724-1845  
Fax: 617-726-5079  
Email: deisboec@helix.mgh.harvard.edu 
 
 
 
 
C. Athale et al.: Molecular Decision Process in Tumors 
   
 2
Abstract 
 
 
Experimental evidence indicates that human brain cancer cells proliferate or migrate, yet do 
not display both phenotypes at the same time. Here, we present a novel computational model 
simulating this cellular decision-process leading up to either phenotype based on a molecular 
interaction network of genes and proteins. The model’s regulatory network consists of the 
epidermal growth factor receptor (EGFR), its ligand transforming growth factor-α 
(TGFα), the downstream enzyme phospholipaseC-γ (PLCγ) and a mitosis-associated response 
pathway. This network is activated by autocrine TGFα secretion, and the EGFR-dependent 
downstream signaling this step triggers, as well as modulated by an extrinsic nutritive glucose 
gradient. Employing a framework of mass action kinetics within a multiscale agent-based 
environment, we analyze both the emergent multicellular behavior of tumor growth and the 
single-cell molecular profiles that change over time and space. Our results show that one can 
indeed simulate the dichotomy between cell migration and proliferation based solely on an 
EGFR decision network. It turns out that these behavioral decisions on the single cell level 
impact the spatial dynamics of the entire cancerous system. Furthermore, the simulation 
results yield intriguing experimentally testable hypotheses also on the sub-cellular level such 
as spatial cytosolic polarization of PLCγ towards an extrinsic chemotactic gradient. 
Implications of these results for future works, both on the modeling and experimental side are 
discussed. 
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1. Introduction 
 
This paper proposes a model of gene-protein interactions integrated in an agent-based system. 
We use the system to simulate the ability of cancer cells to ‘switch’ between migrating and 
proliferating phenotypes and argue that this molecular ‘decision-process’ is capable of 
reproducing some of the experimentally observed, multicellular spatio-temporal dynamics of 
brain tumor expansion. The smallest unit of our model is a molecular species which interacts 
with other molecules within and across sub-cellular compartments as well as with local 
microenvironment. The dynamic change in concentration of these molecular species both 
inside and around the tumor cell guides its phenotypic behavior. Therefore, a particular novel 
feature of our study here is the explicit modeling of the feedback effects from molecular-level 
dynamics into cellular behavior. This single-cell decision in turn affects the overall tumor 
growth dynamics and as such yields a truly multi-scale cancer model. 
 
1.1.  Dichotomy of Glioma Cells 
 
For highly malignant brain tumors, i.e., gliomas, Giese et al. (1996) first proposed dichotomy 
between the phenotypes of migration and proliferation in such cells. The authors argue that 
these two fates appear to exclude each other such that cells that proliferate do not migrate and 
vice-a-versa. However, the exact molecular mechanism governing this suggested switch has 
not yet been clearly established. Tissue cell invasiveness of gliomas is considered a major 
reason for the poor outcome of patients suffering from the disease (reviewed in Berens and 
Giese, 1999), emphasizing the need to better understand the tumor biology governing such 
dichotomy. Our model aims to address some of these issues by examining the spatio-temporal 
dynamics of the molecular processes that guide the decision between motile and proliferative 
traits of a cancerous cell, and hence determine multicellular tumor growth dynamics. In our 
C. Athale et al.: Molecular Decision Process in Tumors 
   
 4
model, we choose to investigate the role of the epidermal growth factor (EGF) receptor 
(EGFR)-mediated signaling pathway since both, in vitro and in vivo experiments with glioma 
cells have shown it to be involved in both the proliferative as well as the migratory response 
(Chicoine and Silbergeld, 1997). 
 
1.2.  Previous Works on EGFR-Pathway Modeling  
The effect of EGFR activation on cancer cells is diverse and complex (Prenzel et al., 2000) 
yet earlier studies of molecular interaction models in single cells have already examined 
various quantitative aspects of this multi-functional pathway. For instance, a model on the 
mitotic effect of ligand-based EGFR stimulation has correlated DNA synthesis with receptor 
occupancy (Wiley and Cunningham, 1981). Lauffenburger and Linderman (1996) then 
incorporated the linear relationship of cell proliferation in response to EGFR occupancy into a 
phenomenological model, which we use in our work here. Endocytosis is a major regulator of 
EGFR receptor trafficking (Resat et al., 2003; Starbuck and Lauffenburger, 1992) and 
influences signaling. Moreover, Brightman and Fell (2000) demonstrated that the differences 
in effect of EGF and nerve growth factor (NGF) on the same network were due to differential 
feedback. Such diverse effects of EGFR signaling are due mainly to the dynamics of 
downstream pathways as shown by Shvartsman et al. (2002a). Interestingly, a recent and 
detailed model has demonstrated the robustness of this network to large variations in initial 
values (Schoeberl et al., 2002). Furthermore, spatial 2D models of EGFR signaling have also 
examined pattern generation with multiple cells (Shvartsman et al., 2002b) as well as self-
organization of spatial-polarization in single cells in 2D that use EGFR-like autocrine 
signaling (Maly et al., 2004). Additionally, a study of the spatial range of autocrine signaling 
in the EGFR system established the rapid and local nature of autocrine ligand capture 
(Shvartsman et al., 2001). It thus noteworthy that paracrine and juxtacrine signaling by TGFα 
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(as the EGFR ligand) has been modeled in the past using linearized coupled ordinary 
differential equations (Owen and Sherratt, 1998) and shown to be applicable to pattern 
formation (Owen et al., 2000). We incorporate several components from these previous 
concepts in our model, as will be described in the subsequent sections. 
 
1.3. Previous Works on Tumor Modeling  
 
Briefly, earlier computational models of tumor growth have focused exclusively on either 
migratory or proliferative behavior. On the migratory side, models for instance examined 
oscillations in the invasive speed (Perumpanani et al., 1996) and obtained invasiveness 
parameters by model-based analysis (Tracqui et al., 1995). Other works focused on 
proliferative behavior. For example, a reaction-diffusion and pH-based model was used to 
examine the transition from benign to malignant cancer (Gatenby and Gawlinski, 1996). 
Another model studying spheroid growth involving positive feedback initiated by cell-cell 
interactions showed improved fits to experimental data (Marusic et al., 1991). Important for 
our efforts here, more recent approaches have combined both invasion and proliferation. 
These include efforts to fit the model to patient data on tumor growth dynamics (Tracqui, 
1995), predict three dimensional dynamics using microscopic parameters (Kansal et al., 
2000), employ differential diffusion in regions of the brain (Swanson et al., 2000) and 
incorporate cellular physiology like mitosis, apoptosis, necrosis, and nutrient uptake 
(Dormann and Deutsch, 2002). Our own agent-based ‘microscopic-macroscopic’ brain tumor 
model, which includes proliferation and migration as well as cellular physiology (Mansury et 
al., 2002) has recently been extended to include a simplified network of two interacting genes, 
TenascinC and proliferating cell nuclear antigen (PCNA) that correlate with the cell 
phenotype of migration and proliferation, respectively (Mansury and Deisboeck, 2004b). 
Using this multicellular framework, in here we simulate the phenotypic switch from cell 
migration to proliferation and vice-a-versa, and examine its effects on growth factor- and 
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nutrient dependent tumor growth dynamics while maintaining a molecular “resolution” on the 
single cell level. 
 
1.4.  EGFR-Pathway Modeling Concept and Experimental Evidence 
 
We model the EGFR-mediated signaling pathway as a network of interacting genes and 
proteins1. This pathway has been demonstrated to cause invasiveness in three human glioma 
cell lines in co-culture with fetal rat brain aggregates (Penar et al., 1997), a result confirmed 
by activation of EGFR in cultured glioma cells by autocrine transforming growth factor-α 
(TGFα), which led to both increased migration and scattering (El-Obeid et al., 1997). On the 
other hand, proliferation responses in gliomas have been observed in culture studies of EGFR 
activation with TGFα in vitro (Rubenstein et al., 2001), within a co-culture system (El-Obeid 
et al., 2002), in tissue samples from patients (von Bossanyi et al., 1998) and with external 
EGF-stimulation in cell culture (Li et al., 2003). Taken together, these findings suggest that 
EGFR activity itself is ambiguous for deciding the phenotype of the cell. We then argue that 
differential processing of the signal downstream in the EGFR-cascade (Wells, 1999) can 
cause the phenotypic decision. 
 
Role of EGFR Downstream Pathways: The EGFR signaling pathway has been implicated in 
numerous downstream pathways, both in fibroblasts (Wells, 1999) as well as gliomas (Besson 
and Yong, 2001; Mischel and Cloughesy, 2003). It mainly affects the following two cascades, 
i.e. (i) PLCγ-Protein-Kinase C, and (ii) ERK-MAPK, which in turn affect multitudes of other 
pathways downstream (Besson and Yong, 2001). PLCγ activation dynamics have already 
been implicated in the switch of cellular behavior as suggested by literature on EGFR 
signaling (Chen et al., 1994; Piccolo et al., 2002; Wang et al., 1998; Wells et al., 1999). 
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Specifically, EGFR mediated PLCγ activity is necessary for cell motility in experiments with 
U87 glioma spheroids (Khoshyomn et al., 1999) as well as breast cancer cells in vitro (Kruger 
and Reddy, 2003). Interestingly, mitosis due to EGFR activation was inhibited by PLCγ in 
fibroblasts (Chen et al., 1994; Chen et al., 1996). Finally, recent evidence has shown that 
subtle differences in the dynamics of PLCγ activation appear to cause the different behavioral 
responses of the tumor cell to EGFR signaling. Specifically, a transient increase in PLCγ 
causes migration whereas a sustained, lower-level activation causes proliferation in human 
breast cancer cells (Dittmar et al., 2002). Thus signal discrimination is likely to be due to 
phospholipaseC-γ (PLCγ) which is activated downstream of EGFR and shows feedback 
inhibition of EGFR activity (reviewed in Wells (1999)). We therefore focus in here on the 
PLCγ-pathway and detail our concept in the following section.  
 
1.4.1.  Cellular ‘Decision Making’  
 
Experimental evidence suggests the following scenario for cellular behavior: 
 
• Glioma cells continually produce basal levels of TGFα while their EGFR pathway is 
active. This has been demonstrated with immuno-staining methods in 88% of 
malignant gliomas of which a random cell subset is actively proliferating (Maruno et 
al., 1991; van der Valk et al., 1997). The proliferative cellular state can be changed by 
an external trigger, e.g. in here, through a diffusing glucose concentration in the cell’s 
microenvironment, followed by rapid uptake of the nutrient and increased 
phosphorylation of the TGFα-EGFR activated complex (Hertel et al., 1986; Steinbach 
et al., 2004).  
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• This step now leads to a rapid increase in the active TGFα-EGFR complex resulting in 
a transient peak in PLCγ, which then triggers the activation of cell migration (Dittmar 
et al., 2002). Based on a direction-sensing mechanism that is guided by the peak 
concentration of active PLCγ, the glioma cell performs chemotaxis towards a nutritive 
site (von Bulow et al., 2001), again, represented in our case by the aforementioned 
replenished source of glucose.  
 
• However, increasing PLCγ activation also reduces TGFα-EGFR activation through 
negative feedback (Chen et al., 1994; Chen et al., 1996; Wells, 1999) which then 
generates a proliferative signal (Dittmar et al., 2002; Kruger and Reddy, 2003). The 
extent of this proliferation signal is linearly dependent on the TGFα concentration 
(Maruno et al., 1991).  
 
In summary, the (virtual) tumor cell in our model therefore migrates if the PLCγ molecule is 
transiently induced by TGF-α-dependent activation of EGFR and modulation by glucose, and 
proliferates if PLCγ is activated in a sustained manner by EGFR activation. This latter state is 
assumed to activate the ERK-MAPK pathway. Since ERK-MAPK signaling has been shown 
to be implicated in the proliferative response (Chajry et al., 1994) we treat this pathway 
implicitly, by replacing it with a signal for cell proliferation.  
 
To model the entire network, we extend our previously developed agent-based modeling 
framework (Mansury and Deisboeck, 2003; Mansury and Deisboeck, 2004a, 2004b; Mansury 
et al., 2002) and add a novel intracellular network module. In the following section, we 
describe the modeling algorithm in detail.  
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2. Mathematical Model 
 
Each autonomous agent or cancer cell is itself made up of three ‘sub-cellular’ compartments, 
i.e., nucleus, cytoplasm and membrane (Figure 1a). These compartments are further resolved 
into spatial sub-compartments directed towards the cardinal directions, i.e., North, South, East 
and West of the grid, and are each connected to two other neighboring compartments by rates 
of in- and out-flows (Figure 1b).  
 
Figure 1 a 
Figure 1 b 
 
Each sub-compartment contains all the molecules involved in the EGFR signaling network 
(Figure 2). Mass balance reactions govern the flux of molecules from one sub-compartment 
to another, as well as reactions defined by the interaction network. Local autocrine secretion 
of TGFα, a concentration profile of glucose and the spatial restriction due to other cells in 
neighboring grid positions form the microenvironment of each cell (see also section 2.3.). 
Thus, there is both chemoattraction by glucose and by TGFα. The latter has been shown in 
mammalian systems to be captured rapidly by cells, and therefore can act in an autocrine and 
juxtacrine (affecting neighboring cells) manner (Kempiak et al., 2003; Owen and Sherratt, 
1998; Shvartsman et al., 2001).  
Figure 2 
 
2.1.  Network Model Balance Equations  
 
We have modeled the molecular network as a mass balance kinetic model with variables 
describing the state of the system and rate constants. The evolution over time of a variable 
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(molecular concentration) is represented by ordinary differential equations. Our network 
model consists of 13 state variables and 30 constants. The autocrine activation of the TGFα 
transcription activation and inhibition of TGFα-EGFR phosphorylation by PLCγ is modeled 
as an enzyme-catalyzed Michaelis-Menten reaction. The overall layout of the interaction 
network is described in Figure 2. Each molecular species is represented for simplicity as a 
variable Xn, where n is its identifier, as listed in Table 1.  
 
Table 1 
 
Each of the reactions is briefly described here and is primarily based on peer-reviewed work 
published in the literature. Parameters and the source for the values are listed in Table 2.  
 
Table 2 
 
To summarize the reactions modeled, the EGFR-ligand-binding module includes the ligand 
TGFα (X1) which binds to the receptor EGFR (X2) and rapidly dimerizes to 2TGFα-EGFR 
(X3), as modeled by Starbuck and Lauffenburger (1992). X3 is then auto-phosphorylated to 
2ppTGFα-EGFR (X4) and the complex is internalized, referred to as TGFα-EGFRi (X5) 
(Brightman and Fell, 2000; Schoeberl et al., 2002). The X3 phosphorylation rate is enhanced 
by intracellular glucose (X13) (Hertel et al., 1986; Steinbach et al., 2004), which was taken up 
from the environment. These processes are represented by Eq. (1-4): 
 
7921131
1 XkXXkXk
dt
dX ⋅+⋅⋅−⋅= − ,       (1) 
285821131
2 XkXkXXkXk
dt
dX ⋅−⋅+⋅⋅−⋅= −− ,      (2) 
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[ ] 4
112
112
4233133211211
3 122 X
XK
XVXkXkXwXkXkXXk
dt
dX
M
M
g ⋅+
⋅+⋅+⋅−⋅+⋅−⋅⋅−⋅⋅⋅= −− ,
            (3) 
[ ] 4
112
112
44421332
4 1 X
XK
XVXkXkXwXk
dt
dX
M
M
g ⋅+
⋅−⋅−⋅−⋅+⋅= − .    (4) 
 
The cytoplasmatic X5 complex, in itself inactive (French and Lauffenburger, 1997), 
dissociates reversibly to cytoplasmic TGFα (X6) and EGFR (X7) as represented by Eq. (5-7): 
 
557654433
5 22 XkXXkXkXk
dt
dX ⋅⋅−⋅⋅⋅+⋅+⋅= − ,     (5) 
66812286876555
6 XkXkXkXkXXkXk
dt
dX ⋅−⋅+⋅+⋅−⋅⋅−⋅= −− ,   (6) 
7791571076555
7 XkXkXkXXkXk
dt
dX ⋅−⋅+⋅−⋅⋅−⋅= − .     (7) 
 
It has also been shown that increased internalization of X3 and X4 leads to down-regulation of 
EGFR RNA (X9) expression and thus, diminished protein content (Hamburger et al., 1991). 
Conversely, EGFR activation by ligand binding increases TGFα RNA (X8) synthesis. Both 
RNA species are also being transcribed and translated at a constitutive rate (Maruno et al., 
1991; van der Valk et al., 1997) and both, protein and RNA are constantly degraded (Mader, 
1988) as denoted by Eq. (8, 9): 
 
814113
8 XkCk
dt
dX ⋅−⋅= ,         (8) 
41916117
9 XVXkCk
dt
dX ⋅+⋅−⋅= ,        (9) 
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where C1 is the constant pool of nucleotides. The increased phosphorylated TGFα-EGFR 
surface complex raises the rate of transition from inactive PLCγ (X10) to active PLCγ (X11); 
this active PLCγ in turn exhibits negative feedback inhibition of X4. (Chen et al., 1994; Chen 
et al., 1996; Wells, 1999) as represented by Eq. (10, 11): 
 
[ ] 411220112110 XXCkXkdt
dX ⋅−⋅−⋅= ,       (10) 
[ ] 112141122011 XkXXCkdt
dX ⋅−⋅−⋅= ,       (11) 
 
where C2 is the constant total PLCγ concentration. The intra-cellular glucose concentration 
(X13) is increased by uptake (Noll et al., 2000) from the extracellular pool (X12 ) and depleted 
by TGFα-EGFR phosphorylation (Eq. (4)) (Hertel et al., 1986; Steinbach et al., 2004), as 
described in Eq. (12): 
 
13321223
13 XXkXk
dt
dX ⋅⋅−⋅= .        (12) 
 
2.2.  Cellular Behavior 
 
2.2.1.  Sub-cellular Molecular Flow 
 
The concentration of a molecule in a given sub-cellular compartment (Xm) over time is 
expressed by Eq. (13): 
 
[ ] joutjjinj XkXXkdtdX ⋅⋅−+⋅= +− 211 ,        (13) 
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where Xj-1 is the concentration of the same molecule in the neighboring compartment before Xj  
and Xj+1 is the compartment after Xj  where j (1 to 4) is the compartment number and kin and 
kout are the flux rate constants into and out of the compartment, respectively (as shown in 
Figure 1b). At every time point at which the reaction network (Eq. (1-12)) is being 
calculated, their flux rates cause a redistribution based on mass-action, thus providing for the 
possibility of dynamic spatial heterogeneity. 
 
2.2.2.  Cell Migration 
 
As stated earlier, using breast cancer cells Dittmar et al. (2002) could show that PLCγ is 
activated transiently and to a greater extent during migration and more gradually in the 
proliferative ‘mode’. We adopt a simple threshold, σPLC, to decide whether the cell should 
undergo migration or not. Thus each cell is evaluated for its migratory potential (M), as given 
by Eq. (14): 
 
[ ]
n
n dt
dXXM 

= 1111 ,         (14) 
 
where dX11/dt is the change in concentration of PLCγ over time (t) and n is the cell number. If 
Mm>σPLC the phenotypic decision threshold is exceeded and the cell becomes eligible to 
migrate (k25 in Figure 2). Evidence from previous studies on the EGFR autocrine signaling 
network points mainly to local factors being responsible for migration (Shvartsman et al., 
2001) and as such, our virtual cells here evaluate the grid points within a von Neumann 
neighborhood for suitability. The mechanism that determines where the cell will migrate is 
decided by the spatial localization of the maximal active PLCγ within a cell. This is based on 
the findings from human breast adenocarcinoma cells in which EGF-induced cell migration is 
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accompanied by the accumulation of PLCγ at the leading edge of migrating cells (Piccolo et 
al., 2002). Specifically, a migrating tumor cell then evaluates the intracellular concentration of 
PLCγ in the compartments that point towards adjacent locations to the North, East, South, and 
West of the cell’s current site. The cell then selects one unoccupied lattice site among these 
four neighbors with a probability that depends on both the maximal concentration of active 
PLCγ at the leading edge, and the level of the so-called search precision, which we define 
below. This process is expressed in terms of a local valuation function for each neighboring 
lattice point j as given in Eq. (15): 
 
[ ] ( ) [ ] PLCj
mj
jjjj XXnnXL Ψ⋅−⋅−= ≤ ][maxarg1, 111111 ,      (15) 
 
where Lj is the value of a grid point in the neighborhood of the cell; the neighboring grid 
locations and compartments are numbered as j (1 to 4). In a given compartment j, X11 is the 
concentration of activated PLCγ, n is the number of cells at that location in the neighborhood 
and m is the total number of compartments (here: m=4). ]1,0[∈ΨPLC  represents the search-
precision parameter that for a given run is held constant for all cells and corresponds to the 
accuracy of the cell’s receptor-mediated direction-sensing mechanism as described in our 
previous work (Mansury and Deisboeck, 2003). Typically we set 7.0=ΨPLC , based on the 
same previous work in which we found that this value leads to the highest average velocity of 
the tumor’s spatial expansion. If Lj≥0 and nj=0 (i.e., that location is unoccupied), then 
location j becomes eligible for the evaluating cell to migrate into it. If there are multiple 
locations that satisfy these two conditions, then the virtual cell randomly selects the next 
location. Note that the search precision parameter PLCΨ  = 0 corresponds to a pure random 
walk, while PLCΨ  = 1 means that cells never commit ‘mistakes’ and always migrate fully 
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biased to the ‘best’ location with the highest level of PLCγ. To see this, consider PLCΨ  = 0. In 
this case, the right-hand side of Eq. (15) is always non negative, which means all locations in 
the cell’s neighborhood are eligible for migration. By contrast, when PLCΨ  = 1, then cells 
always migrate to those locations exhibiting the highest level of PLCγ. As such, this search 
precision parameter determines how sensitive the migratory mechanism is to differences in 
active PLCγ concentration. 
  
2.2.3.  Cell Proliferation 
 
If the change in concentration of active PLCγ is below the migration-threshold, σPLC, yet 
above a set noise threshold, σn (k26 in Figure 2), then the tumor cell will not chose to migrate 
yet has the potential to proliferate. However, an additional condition for proliferation is that 
the total cellular concentration of phosphorylated TGFα-EGFR exceeds a certain threshold 
σEGFR (k27 in Figure 2). Thus proliferation occurs if the proliferative potential Pprolif ≥0. This 
potential is then calculated as given by Eq. (16), 
 
[ ] EGFRprolif XXP σ−= 44          (16) 
 
where X4 is the concentration of ligand bound phosphorylated TGFα-EGFR complex in a cell. 
This function is derived from experimental observations citing cell proliferation in relation to 
an EGF-receptor threshold (Knauer et al., 1984) and a model, which relates receptor 
occupancy to percent maximal proliferation (Lauffenburger and Linderman, 1996). 
Specifically, these works report experimentally measured values of the cell proliferation 
response to EGFR occupancy for some human and rodent cell lines which demonstrated that 
σEGFR is reached at 25% of the total receptor concentration.  
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It is noteworthy that we impose a limit on the number of cells that can proliferate in a given 
time period based on the Gompertz growth curve (Marusic et al., 1994). Furthermore, once a 
cell has been committed to proliferate, the newly divided cell will occupy one of the randomly 
chosen empty lattice sites in the von Neumann neighborhood. The time taken for division is 
delayed by ten iterations. This delay is motivated by the experimental finding that typical cell 
cycle times of glioma cells are approximately 26 hours, while the maximal migration rate is 
~20 µm/hour (Hegedus et al., 2000). The scaled size of one of our lattice grid points is ~20 
µm and so expansion due to cell proliferation over one grid point requires an order of 
magnitude (i.e., 26 times) more time than migration-driven expansion. 
 
2.2.4.  Cell Quiescence 
 
For a cell to transition to a quiescent phenotype, it has to fulfill the following conditions: (i) a 
decline in PLCγ-concentration over time below the threshold σPLC, and (ii) a concentration of 
2ppTGFα-EGFR of less than σEGFR. Under these conditions, the cell neither divides nor 
proliferates and we refer to this phenotype in our model as quiescent.  Cell death or apoptosis 
is currently not included in our model. 
 
2.3.  Extracellular Grid 
 
We employ a discrete lattice grid that represents a virtual slice of brain tissue. Specifically, 
the extracellular environment is modeled as a uniform 2D space consisting of a grid with 200 
x 200 points in size. Each grid point can be occupied by only one cell at the same time. One 
single distant source of replenished nutrients, simulating the anatomical equivalent of a cross-
sectional blood vessel, is located in the North-Eastern (NE) quadrant of the grid. This nutrient, 
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represented by glucose, diffuses at a fixed rate uniformly over the lattice (X12). Its flux (Js) 
follows Fick’s First Law of Diffusion as given by Eq. (17), 
 
1
1
+⋅∂
∂⋅−=
nx
CDJ ss           (17) 
 
where Cs is the concentration, x distance in one dimension, D is the diffusion coefficient of 
the molecule for the medium, and n is the number of cells at a given location. Since we allow 
only one cell per lattice point, if a cell is present at that point (n=1), the flux due to diffusion 
is reduced by half. 
 
We assume Dirichlet boundary conditions for the diffusing glucose, where the value is fixed 
at zero at the edges. The autocrine secreted protein growth factor TGFα is also deposited on 
grid points in the neighborhood of a cell at the rate given by Eq. (1) and Table 2. It is only 
replenished if a cell is located in an adjacent grid point. Thus TGFα is an autocrine produced 
hormone which can, in addition, act in a paracrine as well as juxtacrine manner. Previous 
work has shown that the capture time for autocrine ligands of EGFR is extremely short 
(Shvartsman et al., 2001), and as such we can treat it for now as not diffusing, rather as a 
residual chemical ‘track’ marking a lattice location previously occupied by a cell. Finally, this 
TGFα protein outside the cell is also assumed to have a rate of degradation. 
 
3. Results 
 
Our code is implemented in Java (Sun Microsystems, Inc., USA) and uses the RePast (version 
2.0) agent-based modeling toolkit (http://repast.sourceforge.net), combined with in-house 
developed classes for representing molecules, reactions and sub-cellular compartments as a 
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set of hierarchical objects. For a typical simulation run with three different random number 
seeds and scanning seven parameter values (21 runs) the algorithm required 18 hrs 46 min of 
CPU time on a computer with dual Intel Xeon 2.3GHz processors, connected via gigabit 
Ethernet to the central file storage system and running Linux.  
 
3.1.  Multi-cellular Dynamics  
 
We simulate the expansion of the multicellular tumor from its initial central seed towards the 
peak of glucose located in the NE quadrant of the grid. The time it takes for the first migrating 
cell to reach the edges of this peak is used as a measure of the tumor system’s spatio-temporal 
expansion dynamics. Figure 3a demonstrates that when the PLCγ-dependent cell decision 
threshold σPLC is very low, the spatio-temporal expansion of the tumor is accelerated as the 
cancerous system requires less time to reach the source. Increasing this threshold (decreases 
the probability of a cell attaining the migratory phenotype and thus) slows the tumor system 
down until, beyond a minimum expansion velocity at a σPLC of approximately 3.5x10-3 nM/s, 
the system plateaus at a σPLC of roughly 5x10-3 nM/s. Correspondingly, as σPLC increases, the 
ratio of migrating to proliferating cells decreases, in fact approaching zero when no cell 
migration occurs anymore beyond a σPLC of ~5x10-3 nM/s (Figure 3b). Combined, these two 
figures confirm that a smaller proportion of migrating cells yields slower rates of overall 
tumor expansion. 
 
Figure 3 a 
Figure 3 b 
 
3.2. Sub-cellular Dynamics  
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The 2D snapshots at four consecutive time points depict the spatial patterns of the three 
cellular phenotypes, i.e., proliferative, migratory and quiescent tumor cells. The migratory 
decision threshold (σPLC) was set at 0.001 to ensure stable phenotypes and fast expansion 
(Figure 4a) with a ratio of migratory to proliferative cells approximating five (compare with 
Figure 3b) at the endpoint of the run which is reached when the first migrating cell enters the 
edge of the NE quadrant (Figure 4b). The plots describe a mixed-phase of expansion, where 
both phenotypic traits, i.e. migration and proliferation occur within the cancerous cell 
population. 
 
Figure 4 a 
Figure 4 b 
Figure 4 c 
 
On the molecular level, we first note that X1 (TGFα protein) is homogenously deposited in the 
extracellular von Neumann neighborhood (Figure 4c). The sub-cellular profile of protein 
components of the EGFR-network within this ‘first’ migratory cell shows that X4 (2pp-TGFα-
EGFR) is also homogeneously distributed in the cell membrane in all directions. Conversely, 
X11, i.e., the concentration of active PLCγ displays a polarized pattern within the cytoplasm. 
Specifically, the maximal PLCγ concentration [i.e., 0.16 nM] resides in the cytosolic 
compartment closest to the NE quadrant where the glucose source is located.  
 
4. Discussion and Conclusions 
 
Experimental evidence suggests that a molecular switch operates between the phenotypes of 
proliferation and migration in highly malignant brain tumor cells. To investigate this behavior 
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further, we have integrated here a sub-cellular decision-making gene-protein network into a 
previously developed multiscale, agent-based modeling environment. The results demonstrate 
that this combined molecular-microscopic-macroscopic algorithm is capable of producing 
ranges of behavior at distinct scales, solely by varying the value of the molecular parameter, 
σPLC. Specifically, lowering this cellular phenotypic decision threshold of phospholipaseC-
γ leads to fast multicellular tumor expansion while raising the threshold value yields slower 
spatial expansion rates, conferred by a smaller portion of migratory cells within the system. 
Interestingly, this behavior is not smooth; rather it indicates a phase transition at a σPLC of 
roughly 2.5 x 10-3 nM/s. One can argue that this is an emergent property of the system since 
no a priori condition in the algorithm forces such behavior. Similarly, at the single cell level, 
the polarized localization of active PLCγ in the first migratory cell to reach the edge of the 
glucose source is also an emergent phenomenon, since the flux constants for each 
compartment are identical. The latter is consistent with previous experimental work, in which 
EGFR-activation-dependent migration of human adenocarcinoma cells was accompanied by 
translocation of PLCγ to the leading edge (Piccolo et al., 2002). In addition, our model 
predicts a lack of polarization in EGFR ligand-receptor complex at the membrane at least for 
this ‘first’ migratory cell. While this appears to be in accordance with previous reports (Bailly 
et al., 2000) it requires further, more detailed investigation of different phenotypes as well as 
of cells at other locations and at different time points in the system.   
 
The ability of our system to simulate tumor growth over several orders of magnitude driven 
by a decision making gene-protein network allows us to examine both the molecular 
signature that defines the phenotypic switch as well as the multicellular patterns that in turn 
may serve as a macroscopic systems ‘read-out’ for dynamical changes in its molecular 
profiles. At the moment, our virtual biosystem operates with only two genes, i.e. TGFα and 
EGFR, due to the data-rich nature of this network. However, the extensibility of the platform 
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will allow us to add multiple genetic interaction networks and simulate their behavior over 
multiple scales. A comparison of such simulations with experimental data generated using e.g. 
cDNA and oligonucleotide arrays to study gliomas (e.g., Mariani et al., 2001; Sallinen et al., 
2000) is likely to yield a powerful virtual discovery platform through (i) designing in silico 
experiments, (ii) developing novel hypotheses, and (iii) testing them by guiding specific 
experimental work which can provide further modeling input. It is thus essential that most of 
the predicted dynamics of molecular species concentration and localization in our modeling 
platform, at both the cellular and multicellular level, are experimentally testable. For example, 
the simulation output of the spatial localization of the proteins can be queried at every single 
time point by immuno-staining or even live cell fluorescence microscopy and proteomic 
approaches to test their phosphorylation status. Compartmental flux rates for cell surface and 
cytoplasmic molecules can also be experimentally estimated using methods like fluorescence 
recovery after photobleaching (FRAP) and fluorescence loss in photobleaching (FLIP) in 
living cells (Axelrod et al., 1976). Lastly, receptor association and dissociation rates have 
already been measured mostly by radioactively labeled ligand binding, followed by model 
fitting to estimate the parameters of interest (French et al., 1995).  
 
However, the signaling model adopted in this first approximation here is admittedly simple by 
design. For instance, we do not yet include explicitly any components of the ERK pathway, 
nor do we consider the signaling downstream of PLCγ or the Ca2+ signaling that is associated 
with it. In addition, at the cellular level, there is currently no treatment of mechanical or pH-
related aspects to tumor growth either. In future work we will therefore step-wise add other 
relevant aspects including environmental factors such as mechanical stress, known to restrict 
the expansion of tumors in vitro, in an effort to study the interaction of the chemical and 
physical interactions and their effect on the tumor growth dynamics at various scales.  
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Nonetheless, already in its present form, we argue that this platform is an important first step 
in realizing a fully validated multiscale molecular and multicellular in silico model of tumor 
growth. If combined with proper experimental input, this algorithm will prove useful in 
improving our understanding of tumor biology, not limited to brain tumors, and has the 
potential to help guide future research in the quest for designing and developing more 
effective molecular anti-cancer therapeutics, with systems impact. 
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Table and Figure Legends 
 
Table 1. Shown here are the variables of the network model and the molecular species 
they represent. The table includes the initial values in [nM] and the inter-compartmental flux 
rates [s-1] with their respective literature sources. Reasonable estimates were used where no 
published values were available.  
 
Table 2.  Listed are the symbols used for the parameters of the equations of the network 
described both in text and Figure 2 as well as their values and the related literature sources. 
All first order rate constants are listed in terms of [s-1], second order in [M-1s-1] and 
cooperative reaction constants are given in terms of [nM]. 
 
Figure 1.  The spatial compartmentalization of a tumor cell is depicted schematically. (a) 
Each cell consists of a central nucleus, surrounding cytoplasm and a membrane compartment. 
These compartments are then divided into four sub-compartments in the cardinal directions, 
each connected to two others. The gray sub-compartmental region is further detailed in (b). 
Here, the intra-compartmental flux consists of a rate of inflow (kin) and outflow (kout) as 
represented by solid arrows, while the stippled arrows indicate the exchange of mass between 
different compartments as a result of the gene-protein interaction network (see Figure 2). 
 
Figure 2. The figure depicts the implemented gene-protein interaction network of the 
TGFα-EGFR signaling pathway. Each arrow represents a reaction that is in turn represented 
by a rate constant referred to in Table 2. The arrows that start from a molecule species and 
terminate in the environment signify rates of degradation whereas those with stippled lines 
with either plus (+) or minus (-) signs indicate positive and negative feedback regulation, 
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respectively. The gray arrows represent the cell’s phenotypic ‘decision’ of entering into a 
proliferative or migratory ‘mode’.  
 
Figure 3. The plots describe the effect of varying σPLC (x-axis) in [nM/s] on (a) the time 
in [min] it takes for the first migratory tumor cell to reach the source of glucose in the NE 
quadrant (y-axis), and on (b) the ratio of migrating to proliferating cells (y-axis) within the 
tumor system. The error bars indicate the standard deviation between ten runs using different 
random number seeds. 
 
Figure 4. The figure shows the spatial expansion of the tumor in a single run with σPLC = 
0.001. (a) The 2D tumor snapshots display migrating (black), proliferating (white), and 
quiescent cells (gray-striped) as well as the empty lattice grid (light-gray) and grid sites with 
the diffusing nutrient glucose (dark-gray). The (red) circle in the NE quadrant indicates the 
initial location of the nutrient source from which glucose diffuses. Depicted is the tumor 
progression at time points t = 50, 300, 400 and 502; the migrating tumor cell that first enters 
the edge of the glucose source is highlighted (yellow) in (b) and further magnified. (c) The 
sub- and extracellular localization of three molecular protein species within this ‘first’ 
migratory cell is plotted in 2D. These proteins include extracellular TGFα (dark-red) in the 
von Neumann neighborhood, phosphorylated TGFα-EGFR located in the cell membrane and 
active PLCγ within the cytosol. The color-bar indicates the concentration range in [nM] of the 
molecular species with dark-blue depicting zero (for cellular ‘geography’ compare with 
Figure 1). The gray arrow points to the location of the glucose source relative to the cell. 
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Tables 
 
Table 1. 
 
Symbol Variable Initial 
Values 
[nM] 
Sub-cellular 
Flux Rates 
Reference 
X1 TGFα extracellular protein 1 5 x 10-2 (Dowd et al., 
1999) 
X2 EGFR cell surface receptor 25 1 x 10-4 (Maly et al., 
2004) 
X3 Dimeric TGFα-EGFR cell surface 
complex 
0 1 x 10-4 (Maly et al., 
2004) 
X4 phosphorylated active dimeric 
TGFα-EGFR cell surface complex 
0 1 x 10-4 (Maly et al., 
2004) 
X5 Cytoplasmic inactive dimeric 
TGFα-EGFR complex 
0 1 x 10-2 (Hirschberg et 
al., 1998) 
X6 Cytoplasmic EGFR protein 0 1 x 10-2 (Hirschberg et 
al., 1998) 
X7 Cytoplasmic TGFα protein 1 1.5 x 10-2 (Hirschberg et 
al., 1998) 
X8 EGFR RNA 1 1 x 10-2 (Kues et al., 
2001) 
X9 TGFα RNA 0 2 x 10-2 (Kues et al., 
2001) 
X10 PLCγ Ca-bound 1 No-flux 
modeled 
(Piccolo et al., 
2002) 
X11 PLCγ active, phosphorylated, Ca-
bound 
1 2 x 10-4 (Kim et al., 
1990) 
X12 Nucleotide pool 5 No-flux 
modeled 
Estimate 
X13 Glucose cytoplasmic 1 3 x 10-3 (Pfeuffer et al., 
2000) 
X14 Glucose extracellular 0 3 x 10-5 min-1 (Jain, 1987) 
 
 
Table 2.  
 
Param
eter 
Value Description Reference 
k1 3 x 107 TGFα-EGFR cell-surface 
complex formation rate 
(De Crescenzo et al., 2000; Kramer et 
al., 1994; Rutten et al., 1996) 
k-1 3.8 x 10-3 Rate of dissociation of TGFα-
EGFR cell-surface complex 
(De Crescenzo et al., 2000; Kramer et 
al., 1994; Rutten et al., 1996) 
k2 1 x 10-3 Rate of TGFα-EGFR 
phosphorylation 
(Brightman and Fell, 2000) 
k-2 1 x 10-6 Rate of TGFα-EGFR de-
phosphorylation 
(Brightman and Fell, 2000) 
k3 5 x 10-5 Rate of phosporylated TGFα-
EGFR internalization 
(Schoeberl et al., 2002; Starbuck and 
Lauffenburger, 1992) 
k4 5 x 10-5 Rate of cell-surface TGFα- (Starbuck and Lauffenburger, 1992) 
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EGFR internalization 
k5 1 x 10-2 Dissociation rate of 
cytoplasmic TGFα-EGFR 
(Schoeberl et al., 2002; Starbuck and 
Lauffenburger, 1992) 
k-5 1.4 x 105 Reverse dissociation rate of 
cytoplasmic TGFα-EGFR 
(Schoeberl et al., 2002; Starbuck and 
Lauffenburger, 1992) 
k6 1.67 x 10-4 Rate of cytoplasmic EGFR 
protein degradation 
(French and Lauffenburger, 1997; 
Wiley and Cunningham, 1981) 
k7 1.67 x 10-4 Rate of cytoplasmic TGFα 
protein degradation 
(French and Lauffenburger, 1997; 
Wiley and Cunningham, 1981) 
k8 5 x 10-3 Rate of cytoplasmic EGFR 
insertion into the membrane 
(Schoeberl et al., 2002; Starbuck and 
Lauffenburger, 1992) 
k-8 5 x 10-5 Rate of cell-surface EGFR 
internalization 
(Starbuck and Lauffenburger, 1992) 
k9 1 Rate of membrane insertion 
and secretion of TGFα 
(Borrell-Pages et al., 2003; Shvartsman 
et al., 2002a; Tang et al., 1997) 
k10 0.01 Rate of down-regulation of 
EGFR expression by the 
TGFαEGFR complex 
(Hamburger et al., 1991) 
k11 0.01 Degradation of extracellular 
TGFα  
Estimate 
k12 5 [molecules/min] Rate of 
translation of EGFR RNA 
(Mader, 1988) 
k13 2.17 Basal transcription rate 
EGFR RNA [molecules/min] 
(Mader, 1988) 
k14 1.2 x 10-3 EGFR RNA degradation rate 
[molecules/min] 
(Mader, 1988) 
k15 5 Rate of translation of TGFα 
[molecules/min] 
(Mader, 1988) 
k16 1.2 x 10-3 TGFα RNA degradation rate 
[molecules/min] 
(Mader, 1988) 
k17 12 Basal transcription rate 
TGFa_rna [molecules/min] 
(Mader, 1988) 
k18 KM1, VM1, 
w1 
Induction of TGFα 
transcription by activated 
TGFα-EGFR at the cell 
surface 
- 
KM1 1 Km of TGFα RNA 
transcriptional activation 
Estimate 
VM1 5 Rate of TGFα RNA 
transcriptional activation 
Estimate 
w1 1 Weight of Hills Coefficient of 
TGFα RNA activation 
Estimate 
k19 0.1 Enhanced rate of PLCγ 
activation by EGFR 
(Haugh et al., 2000) 
k20 0.1 Basal rate of activation of 
PLCγ 
(Haugh et al., 2000) 
k21 0.05 Rate of in-activation of PLCγ (Haugh et al., 2000) 
k22 KM2, VM2, 
w2 
PLCγ dependent rate of de-
phosphorylation of 
phosphorylated TGFα-EGFR 
- 
KM2 5 Km PLCγ inhibition of 
phosphorylated surface 
TGFα-EGFR 
Estimate 
VM2 0.25 PLCγ inhibition rate of LR* Estimate 
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w2 1 Weight of hills coefficient 
PLCγ inhibition of 
phosphorylated surface 
TGFα-EGFR 
Estimate 
k23 0.7 Lumped rate of Glucose 
uptake 
(Noll et al., 2000) 
k24 0.01 Increased rate of TGFα-
EGFR phosphorylation by 
Glucose 
(Hertel et al., 1986; Steinbach et al., 
2004) 
wg 5.0 Weight of increase in rate of 
TGFα-EGFR phosphorylation 
by Glucose 
Estimate 
k25 Eqs. 14, 15 Migratory signal (Dittmar et al., 2002; El-Obeid et al., 
1997; Kruger and Reddy, 2003) 
k26 Eq. 14 Mitotic signal I (Knauer et al., 1984; Maruno et al., 
1991; Schoeberl et al., 2002) 
k27 Eq. 16 Mitotic signal II (Chen et al., 1994; Dittmar et al., 2002; 
Knauer et al., 1984; Kruger and Reddy, 
2003; Maruno et al., 1991) 
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Figure 1. 
 
 
 
(a)           (b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Extracellular space
Cytoplasm
M
em
br
an
e
kin
kout
Nucleus
M
em
br
an
e
C. Athale et al.: Molecular Decision Process in Tumors 
   
 35
Figure 2. 
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Figure 3 (a). 
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Figure 3 (b).  
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Figure 4. 
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Footnotes 
 
1. In those instances where no glioma data were available in the literature, we have used 
published EGFR data derived from other relevant experimental systems, primarily 
from other human carcinoma cell lines. 
 
 
